In Vivo Gene Function Studies
Inquiry
As a preclinical CRO specializing in oncology, Alfa Cytology offers comprehensive in vivo gene function study services. Leveraging advanced gene modulation tools (overexpression, knockout, knockdown) and in vivo model systems, our senior scientists are committed to delivering high-quality, reproducible in vivo functional study solutions tailored to meet your specific research needs.
Introduction to In Vivo Gene Function Studies
In vivo gene function studies are an indispensable component of cancer research, enabling the evaluation of gene functions in tumor initiation, progression, and therapeutic response at the level of the intact organism. By evaluating gene functions in animal models such as mice, in vivo studies faithfully recapitulate tumor biological behaviors within the complete physiological and pathological environment, encompassing tumor growth kinetics, metastatic dissemination patterns, angiogenesis, immune microenvironment remodeling, metabolic adaptation, and drug responses. Compared with in vitro experiments, in vivo studies preserve the intricate interactions between tumors and the host, enabling comprehensive assessment of the impact of gene functions on various components of the tumor ecosystem and generating data with greater clinical relevance. Through in vivo models, researchers can assess the relationship between target dependency and tumor growth inhibition, predict clinical efficacy, explore resistance mechanisms, and determine rational dosing regimens. Furthermore, the pharmacological data obtained from in vivo studies constitute an essential and indispensable component of IND submissions, providing critical evidence to guide subsequent clinical trial design.
Fig. 1 In vivo genome-wide CRISPR/Cas9 gene knockout screen identifies candidate tumor suppressors. (Potts MA, et al.; 2025)
Our Services
Alfa Cytology's in vivo gene function study services cover the entire workflow from gene modulation model establishment to in vivo phenotypic analysis and data interpretation. We support a variety of in vivo models, including cell-derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse models (GEMM), and are compatible with multiple gene modulation approaches (overexpression/knockout/knockdown), delivering reliable in vivo functional data to support your target validation, mechanistic elucidation, and drug development programs.
Available In Vivo Model
We offer a variety of in vivo models to meet the needs of different research stages:
|
Model Type |
Description |
Advantages |
Best Suited For |
| CDX Models |
Genetically modulated tumor cell lines implanted subcutaneously or orthotopically into immunodeficient mice |
Short turnaround time (2–4 weeks), high reproducibility, cost-effective, easy genetic manipulation |
- Target functional validation;
- Preliminary pharmacodynamic evaluation;
- In vivo imaging studies
|
| PDX Models |
Patient-derived tumor tissues directly transplanted into immunodeficient mice |
Preserve the heterogeneity, genetic characteristics, and histopathological features of the original tumor |
- Clinical relevance validation;
- Personalized therapeutic strategy development
|
| GEMMs |
Conditional knockout/knock-in mice |
Genes are expressed under physiological regulation; intact immune system retained |
- Immune microenvironment impact assessment
|
Available Gene Modulation Strategies
Based on research objectives and model types, we offer a range of in vivo gene modulation approaches:
Ex Vivo Modulation and In Vivo Transplantation
Tumor cells are genetically modulated in vitro (overexpression/knockout/knockdown) prior to implantation into mice.
In Vivo Direct Modulation
AAV, lentiviral, or adenoviral vectors carrying the gene of interest or RNAi/CRISPR components are delivered directly into tumors or specific tissues to achieve in situ gene modulation.
Transgenic/Knockout Mouse Models
Constitutive or conditional gene modulation is achieved in specific tissues or systemically using GEMM-based models.
Comprehensive In Vivo Assay
We offer systematic in vivo assay systems that comprehensively evaluate gene function across multiple dimensions:
| Assay Type |
Representative Methods |
Applications |
| Tumor Growth Monitoring |
Caliper measurement, in vivo imaging (bioluminescence/fluorescence) |
Dynamically assess the impact of genes on tumor growth kinetics |
| Metastasis Assessment |
In vivo imaging tracking, tissue dissection, and metastatic foci counting (lung/liver/lymph nodes, etc.) |
Evaluate the impact of genes on tumor metastatic capacity |
| Survival Analysis |
Kaplan-Meier survival curves |
Assess the impact of genes on overall survival of tumor-bearing mice |
| Histopathological Analysis |
H&E staining, IHC/IF (Ki67, Cleaved Caspase-3, CD31, immune cell markers, etc.) |
Evaluate the impact of genes on tumor proliferation, apoptosis, angiogenesis, and immune microenvironment |
| Pharmacodynamic Evaluation |
Combination therapy studies, dose-response analysis |
Assess the impact of gene modulation on drug sensitivity/resistance and evaluate combination therapy strategies |
| PK/PD Correlation Analysis |
Intratumoral drug concentration measurement, target engagement analysis |
Assess target engagement and generate PK/PD data to support IND submissions |
| Biomarker Detection |
Biomarker detection in blood/tissue samples, ctDNA analysis |
Assess molecular responses following target modulation and support biomarker strategy development |
Applications of In Vivo Gene Function Studies
Target Validation
Systematically validate the functional necessity of targets in physiological and pathological microenvironments. Employ in vivo knockout, knockdown, or overexpression models to assess the driving roles of target genes in tumor growth, metastasis, and microenvironment remodeling, thereby confirming their feasibility as drug targets.
Mechanism of Action (MoA) Studies
Elucidate downstream signaling networks and effector mechanisms regulated by targets in the context of intact organisms. Analyze systemic changes in tumor cell proliferation, apoptosis, metabolism, immune microenvironment, and angiogenesis following target gene perturbation to reveal the molecular logic linking targets to tumor phenotypes, providing mechanistic rationale for targeted therapeutic strategies.
Pharmacodynamic Evaluation
Provide proof-of-concept for the in vivo antitumor activity of targeted therapeutics. Utilize genetically modulated in vivo models to systematically assess drug effects on tumor growth inhibition, metastasis blockade, and survival extension, clarifying the relationship between target dependency and efficacy, and generating critical data for preclinical candidate selection.
Resistance Mechanism Studies
Elucidate the functions of resistance-associated genes in resistant in vivo models. Dissect alterations in gene regulatory networks driving resistance, identify key resistance drivers, and uncover combination therapeutic strategies to overcome resistance, providing experimental evidence to guide clinical resistance management.
Service Highlights
- Multiple In Vivo Models: Support for CDX, PDX, and GEMM to meet the full spectrum of research needs, from early target validation to IND-enabling studies.
- Flexible Gene Modulation Approaches: Support for three strategies—ex vivo modulation plus transplantation, in vivo direct delivery, and transgenic/knockout models.
- Comprehensive In Vivo Assay Systems: Coverage of multiple dimensions including tumor growth, metastasis, survival, histopathology, and pharmacodynamic evaluation.
- High Clinical Relevance: PDX and GEMM models preserve tumor heterogeneity and physiological microenvironments, delivering results with greater translational value.
Alfa Cytology understands that physiologically relevant in vivo data are essential for advancing drug discovery programs. We integrate advanced gene modulation tools, clinically relevant animal models (CDX, PDX, and GEMM), and comprehensive in vivo imaging and histopathological platforms to deliver critical decision-making data. Whether you are at the stage of target validation, pharmacodynamic evaluation, or IND-enabling studies, we are here to provide professional support. Contact us to learn how our tailored in vivo solutions can accelerate your project.
Reference
- Potts MA, et al. Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma. Nat Commun. 2025;16(1):7582.
For research use only.
